5 results on '"Ma, Buyun"'
Search Results
2. The biological process of lysine‐tRNA charging is therapeutically targetable in liver cancer.
- Author
-
Zhang, Ruyi, Noordam, Lisanne, Ou, Xumin, Ma, Buyun, Li, Yunlong, Das, Pronay, Shi, Shaojun, Liu, Jiaye, Wang, Ling, Li, Pengfei, Verstegen, Monique M. A., Reddy, D. Srinivasa, Laan, Luc J. W., Peppelenbosch, Maikel P., Kwekkeboom, Jaap, Smits, Ron, and Pan, Qiuwei
- Subjects
LIVER cancer ,CANCER cell migration ,LYSINE ,CANCER cell growth ,TRANSFER RNA ,HEPATOCELLULAR carcinoma - Abstract
Background & Aims: Mature transfer RNAs (tRNA) charged with amino acids decode mRNA to synthesize proteins. Dysregulation of translational machineries has a fundamental impact on cancer biology. This study aims to map the tRNAome landscape in liver cancer patients and to explore potential therapeutic targets at the interface of charging amino acid with tRNA. Methods: Resected tumour and paired tumour‐free (TFL) tissues from hepatocellular carcinoma (HCC) patients (n = 69), and healthy liver tissues from organ transplant donors (n = 21), HCC cell lines, and cholangiocarcinoma (CC) patient‐derived tumour organoids were used. Results: The expression levels of different mature tRNAs were highly correlated and closely clustered within individual tissues, suggesting that different members of the tRNAome function cooperatively in protein translation. Interestingly, high expression of tRNA‐Lys‐CUU in HCC tumours was associated with more tumour recurrence (HR 1.1; P =.022) and worse patient survival (HR 1.1; P =.0037). The expression of Lysyl‐tRNA Synthetase (KARS), the enzyme catalysing the charge of lysine to tRNA‐Lys‐CUU, was significantly upregulated in HCC tumour tissues compared to tumour‐free liver tissues. In HCC cell lines, lysine deprivation, KARS knockdown or treatment with the KARS inhibitor cladosporin effectively inhibited overall cell growth, single cell‐based colony formation and cell migration. This was mechanistically mediated by cell cycling arrest and induction of apoptosis. Finally, these inhibitory effects were confirmed in 3D cultured patient‐derived CC organoids. Conclusions: The biological process of charging tRNA‐Lys‐CUU with lysine sustains liver cancer cell growth and migration, and is clinically relevant in HCC patients. This process can be therapeutically targeted and represents an unexplored territory for developing novel treatment strategies against liver cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. LGR5 marks targetable tumor-initiating cells in mouse liver cancer.
- Author
-
Cao, Wanlu, Li, Meng, Liu, Jiaye, Zhang, Shaoshi, Noordam, Lisanne, Verstegen, Monique M. A., Wang, Ling, Ma, Buyun, Li, Shan, Wang, Wenshi, Bolkestein, Michiel, Doukas, Michael, Chen, Kan, Ma, Zhongren, Bruno, Marco, Sprengers, Dave, Kwekkeboom, Jaap, J. W. van der Laan, Luc, Smits, Ron, and Peppelenbosch, Maikel P.
- Subjects
LIVER cancer ,LIVER cells ,THERAPEUTICS ,TREATMENT effectiveness ,HEPATOCELLULAR carcinoma ,CANCER cells ,CANCER stem cells - Abstract
Cancer stem cells (CSCs) or tumor-initiating cells (TICs) are thought to be the main drivers for disease progression and treatment resistance across various cancer types. Identifying and targeting these rare cancer cells, however, remains challenging with respect to therapeutic benefit. Here, we report the enrichment of LGR5 expressing cells, a well-recognized stem cell marker, in mouse liver tumors, and the upregulation of LGR5 expression in human hepatocellular carcinoma. Isolated LGR5 expressing cells from mouse liver tumors are superior in initiating organoids and forming tumors upon engraftment, featuring candidate TICs. These cells are resistant to conventional treatment including sorafenib and 5-FU. Importantly, LGR5 lineage ablation significantly inhibits organoid initiation and tumor growth. The combination of LGR5 ablation with 5-FU, but not sorafenib, further augments the therapeutic efficacy in vivo. Thus, we have identified the LGR5
+ compartment as an important TIC population, representing a viable therapeutic target for combating liver cancer. Cancer stem cells (CSCs) are thought to be the main drivers for disease progression and treatment resistance in liver cancer. This study identifies the LGR5+ compartment as an important CSC population, representing a viable therapeutic target for combating liver cancer. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma.
- Author
-
Liu, Pengyu, Cao, Wanlu, Ma, Buyun, Li, Meng, Chen, Kan, Sideras, Kostandinos, Duitman, Jan-Willem, Sprengers, Dave, Tran, T C Khe, Ijzermans, Jan N M, Biermann, Katharina, Verheij, Joanne, Spek, C Arnold, Kwekkeboom, Jaap, Pan, Qiuwei, and Peppelenbosch, Maikel P
- Subjects
CARRIER proteins ,PROTEIN binding ,HEPATOCELLULAR carcinoma - Abstract
CCAAT/enhancer-binding protein delta (CEBPD) is associated with the regulation of apoptosis and cell proliferation and is a candidate tumor suppressor gene. Here, we investigated its role in hepatocellular carcinoma (HCC). We observe that CEBPD mRNA expression is significantly downregulated in HCC tumors as compared with adjacent tissues. Protein levels of CEBPD are also lower in tumors relative to adjacent tissues. Reduced expression of CEBPD in the tumor correlates with worse clinical outcome. In both Huh7 and HepG2 cells, shRNA-mediated CEBPD knockdown significantly reduces cell proliferation, single cell colony formation and arrests cells in the G
0 /G1 phase. Subcutaneous xenografting of Huh7 in nude mice show that CEBPD knockdown results in smaller tumors. Gene expression analysis shows that CEBPD modulates interleukin-1 signaling. We conclude that CEBPD expression uncouples cancer compartment expansion and clinical outcome in HCC, potentially by modulating interleukin-1 signaling. Thus, although our results support the notion that CEBPD acts as a tumor suppressor in HCC, its action does not involve impairing compartment expansion per se but more likely acts through improving anticancer immunity. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. Targeting Gene-Virus-Mediated Manganese Superoxide Dismutase Effectively Suppresses Tumor Growth in Hepatocellular Carcinoma In Vitro and In Vivo.
- Author
-
Huang, Fang, Ma, Buyun, Wang, Yigang, Xiao, Ruijuan, Kong, Yanping, Zhou, Xiumei, and Xia, Dajing
- Subjects
- *
LIVER cancer , *MANGANESE , *SUPEROXIDE dismutase , *TUMOR growth , *LABORATORY mice , *THERAPEUTICS - Abstract
Although the treatment methods for hepatocellular carcinoma (HCC) have made a great progress on patient survival rate and life quality, the HCC recurrence still is very high. To explore the novel effective anticancer strategies for HCC, the Cancer Targeting Gene-Viro-Therapy (CTGVT) strategy was applied through oncolytic virus-delivery antitumor gene. In this article, the dual-regulated oncolytic adenovirus Ad-AFP-E1A-E1B(Δ55kDa)-Mn-SOD (briefly named AD55-Mn-SOD) was constructed using a liver cancer-specific α-fetoprotein (AFP) promoter to control replication-essential E1A gene and deliver the novel tumor suppression gene Manganese superoxide dismutase (Mn-SOD). The results indicated that the constructed AD55-Mn-SOD exerted tumor-specific features, and induced dramatic cytotoxicity in HCC cells in vitro and suppress the HCC xenografted growth in nude mice. Moreover, the anticancer mechanism of AD55-Mn-SOD is due to the activation of caspase apoptotic pathway. These data suggested that AD55-Mn-SOD could become a potential anticancer agent for liver cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.